drugset / Trial / NCT01052142
Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma
Phase 1
Completed
12 enrolled
Lipotek Pty Ltd
Royal Adelaide Hospital · collabTrident Clinical Research Pty Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Lipovaxin-MM, a new anti-cancer vaccine, is safe and effective in improving the body's ability to destroy cancer cells in patients with metastatic melanoma.
Timeline
- Start
- 2009-09
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lipovaxin-MM | Vaccine | — | Intravenous |